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Abstract
We present Knowledge Engine for Genomics (KnowEnG), a free-to-use computational sys-
tem for analysis of genomics data sets, designed to accelerate biomedical discovery. It
includes tools for popular bioinformatics tasks such as gene prioritization, sample clustering,
gene set analysis, and expression signature analysis. The system specializes in “knowl-
edge-guided” data mining and machine learning algorithms, in which user-provided data are
analyzed in light of prior information about genes, aggregated from numerous knowledge
bases and encoded in a massive “Knowledge Network.” KnowEnG adheres to “FAIR” princi-
ples (findable, accessible, interoperable, and reuseable): its tools are easily portable to
diverse computing environments, run on the cloud for scalable and cost-effective execution,
and are interoperable with other computing platforms. The analysis tools are made available
through multiple access modes, including a web portal with specialized visualization mod-
ules. We demonstrate the KnowEnG system’s potential value in democratization of
advanced tools for the modern genomics era through several case studies that use its tools
to recreate and expand upon the published analysis of cancer data sets.
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Introduction
The rapid growth of genomics data sets [1] and efforts to consolidate diverse data sets into
common portals [2] have created an urgent need today for software frameworks that can be
easily applied to these genomic “big data” to extract biological and medical insights from them
[3]. Here, we present “KnowEnG” (Knowledge Engine for Genomics, pronounced “know-
ing”), a cloud-based engine that provides a suite of powerful and easy-to-use machine learning
tools for analysis of genomics data sets. These tools, also referred to as “pipelines,” perform
common bioinformatics analyses such as clustering of samples, gene prioritization, gene set
characterization, and signature analysis. The tools are geared toward diverse omics data sets
that can be represented as spreadsheets or tables (genes x samples) that record typical genomic
profiles, such as gene expression, mutation counts, etc., for a collection of samples, at the reso-
lution of individual genes. The pipelines help identify biologically meaningful patterns in the
provided spreadsheet data, through ab initio analysis as well as by contextualizing with prior
knowledge. The utility of KnowEnG is increased by co-localization of its tools with prior
knowledge data sets from a large variety of sources.
Diverse computing environments for KnowEnG
The genomics computing infrastructure of the future has to be adapted to the diverse ecosys-
tem of data sets and tools that will continue to flourish in genomic research. In particular,
tools must be “findable, accessible, interoperable, and reusable” [4], i.e., comply with the
“FAIR” principles that guide the modern vision of biological data science. In recognition of
these principles, software components of the KnowEnG system are packaged using state-of-
the-art technology [5] that makes them highly portable and amenable to scalable execution in
varying computing environments. A convenient way to access the system is through a web
portal that links to a KnowEnG server (https://knoweng.org/analyze/; also see Appendix A in
S1 File) running on Amazon Web Services (AWS). A user can upload their genomics data set
as a spreadsheet and then execute available pipelines (Fig 1A and 1B and Appendix B in S1
File). Often, the resulting outputs of one KnowEnG pipeline can be further analyzed using
another pipeline, and the system facilitates such “handover” between pipelines. For added
security and control, users may also create a personal instance of the KnowEnG server and
web portal using their AWS accounts (Appendix C in S1 File). This design feature can help
meet challenges of heavy computing loads faced by a public analytics server. Computationally
savvy users may invoke the pipelines and avail of additional functionalities through Jupyter [6]
notebooks (https://knowtebook.knoweng.org) from a dedicated KnowEnG server. A third
mode of access, created for cancer researchers, is via the Cancer Genomics Cloud resource
built by Seven Bridges (SB-CGC) [7], in which users may directly access large cancer data sets,
such as those generated by the Cancer Genome Atlas (TCGA) program [8], and analyze them
using KnowEnG pipelines (https://cgc.sbgenomics.com/public/apps#q?search=knoweng)
without transferring the data from AWS. Through these varied access modes, KnowEnG facili-
tates accessibility, interoperability, and reusability of its tools, marking a significant step
towards realizing the “FAIR” vision.
Knowledge Network–guided analysis
An important feature of KnowEnG pipelines is that they can incorporate large-scale prior
knowledge about genes into analyses of the user’s data set. A basic form of such “knowledge-
guided” analysis is already common, in which the researcher performs statistical analysis of an
experimental data set and then interprets the results in the light of prior knowledge from pub-
licly available gene annotation repositories such as Gene Ontology (GO) [9], Reactome [10],
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etc. KnowEnG makes this analytic process more rigorous by adapting its statistical tools to be
directly guided by the vast data in such public repositories of gene annotations and interac-
tions. In doing so, KnowEnG builds on a rich tradition of knowledge-guided analysis methods
that have been previously reported for a variety of biological research tasks including (1) clus-
tering of samples into cancer subtypes [11–14], (2) finding markers and drivers of disease [15–
20], (3) prediction of patient survival [21,22] or cancer metastases [23], (4) characterization of
experimental gene sets [24–28], and (5) prediction of gene functions [29–31]. KnowEnG also
Fig 1. Overview of KnowEnG platform. (A) Typical workflow steps for KnowEnG: genomic analysis on the cloud. (B) Analytical functionalities are
organized as “pipelines” for common tasks such as clustering, gene prioritization, gene set analysis, and signature analysis. Each pipeline offers various
options to customize the analysis, including use of prior knowledge. (C) The KnowEnG Knowledge Network represents prior knowledge that may be
used during analysis. Nodes in the network represent genes and biological properties, and edges represent either annotations of gene properties or
gene-gene relationships. Network contents are summarized on the left with logos of data sources shown on the right. KnowEnG, Knowledge Engine for
Genomics; TCGA, the Cancer Genome Atlas.
https://doi.org/10.1371/journal.pbio.3000583.g001
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breaks the logistical barriers associated with utilizing large databases of prior knowledge, by
co-locating its “knowledge-guided analysis” tools with a diverse knowledgebase compiled
from numerous popular repositories. The knowledgebase is encoded in a massive heteroge-
neous network called the “Knowledge Network,” whose nodes are genes/proteins and whose
edges represent properties (e.g., pathway membership) and mutual relationships (e.g., protein-
protein interaction) of the nodes (Fig 1C). The network represents annotations of 41 different
types from 20 species and 13 different data sources and includes 476 million edges, 405,000
gene nodes, and 178,000 property nodes; the network is regularly updated via a “one-click”
internal system (Appendix A in S2 File). Users typically select the annotation type that is most
relevant for guiding their analysis (Appendix D in S1 File) in the course of launching a pipe-
line. The Knowledge Network is also available as a stand-alone resource that allows subnet-
works associated with a knowledge type to be retrieved (Appendix E in S1 File).
Here, we demonstrate the main functionalities, features, and interfaces of KnowEnG in the
context of 2 influential data sets in cancer genomics [32,33]. We reproduce several key analyses
of the original cancer studies in the KnowEnG system to highlight the ease-of-use with which
multiple analysis pipelines can be invoked to generate publishable general insights and extract
specific hypotheses from the data. We also present novel knowledge-guided analyses on these
data sets that often result in more significant findings and provide a multifaceted narrative of
the insights that the data have to offer. The scope of KnowEnG analytics goes far beyond can-
cer analysis, however, with the system currently supporting analysis of users’ genomics data
from any of 20 model organisms. We explain later (see Discussion) how its tools are broadly
applicable to genomics data sets from any biological domain in any of the supported species.
Results
Overview of 3 “case studies”
We begin with an overview of the case studies used as demonstrations of KnowEnG pipelines.
These pipelines analyze spreadsheets of genes (rows) by samples (columns), which tabulate
numeric data on each gene in each sample condition. The data may come from a variety of
sources, e.g., high-throughput transcriptomics assays using various technologies, mutation
counts at the gene level, copy number variations, etc. These data are then analyzed through
one of the KnowEnG pipelines, depending on the biomedical questions of interest, and the
results are visualized in the platform and optionally passed on to additional pipelines for
deeper investigation (Fig 2A). Additional information and simple instructions for easily repro-
ducing the main analyses presented in this paper on the KnowEnG web server are found in
Appendix F in S1 File.
In Case Study 1 (Fig 2B), we analyzed multiomics data on patients from a pan-cancer study
[32]. We first used the “Sample Clustering” pipeline on somatic mutation data to identify clus-
ters of patients with similar mutation profiles. We used knowledge-guided clustering in this
step and found it to reveal an improved grouping of patients compared to traditional cluster-
ing, as judged by survival characteristics of the resulting clusters. We used the “Gene Prioriti-
zation” pipeline to identify genes that are most associated with each patient group and
characterized the pathways related to those genes using the “Gene Set Characterization” pipe-
line. We also grouped the pan-cancer cohort of patients using other omics data and combined
the results to obtain a single clustering based on all available data types, which we passed to the
“Spreadsheet Visualizer” module to visually explore different aspects of the results including
the improved significance of these clusters with overall patient survival.
In Case Study 2 (Fig 2C), we used the knowledge-guided Gene Prioritization pipeline to dis-
cover genes whose expression (from RNA sequencing [RNA-seq]) associated with each tumor
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type (as defined by tissue of origin) in the pan-cancer data set and found the discovered genes
to include known drivers of the respective cancer types. We used the Gene Set Characteriza-
tion pipeline to perform enrichment analysis of these prioritized genes and identify pathways
and biological processes associated with each cancer type. We also found the prioritized genes
to form a strong signature for the cancer types, in the sense that patient groups identified by
examining expression levels of those genes were as informative of survival as groups identified
from transcriptome-wide profiles.
In Case Study 3 (Fig 2D), we reproduced key findings of a transcriptomic study of esoph-
ageal squamous cell carcinoma (ESCC) [33] using the “Signature Analysis” pipeline. We
assigned subtypes to ESCC patient transcriptomic profiles by relying on previously known sig-
natures of lung squamous cell carcinoma (LUSC) subtypes, which provide clues into prognosis
and chemotherapeutic resistance. We then identified genes and pathways associated with each
ESCC subtype. Our main goal in this case study was to demonstrate how KnowEnG function-
alities can be easily accessed on a third-party platform (Seven Bridges Cancer Genomics
Cloud) where the data set resides. This flexibility allows researchers to seamlessly combine
KnowEnG tools with other specialized tools that are available on the Seven Bridges platform
when undertaking more complex projects with many different analytical components.
In the following sections, we describe each of the above case studies in detail. Our goal is to
present typical usage of KnowEnG pipelines through examples taken from impactful published
Fig 2. Case studies demonstrating knowledge-guided analysis. (A) Each of the KnowEnG analysis pipelines is shown as a box with corresponding
colored arrows connecting to their general inputs and outputs. Because the outputs of a pipeline are often valid inputs for another pipeline, a
convenient “handover” mechanism in the KnowEnG web portal enables chaining together multiple pipelines, facilitating deeper and multifaceted
analysis of the user’s data. (B) The analysis workflow for Case Study 1 with unused pipelines shaded gray. Simple descriptions of the case study–specific
inputs and outputs are provided, along with notes on where to find the detailed methods or figures of the results. The pipeline step of the workflow that
incorporates knowledge-guided analysis is indicated with the blue network icon. (C) Analysis workflow for Case Study 2. (D) Analysis workflow for
Case Study 3. ESCC, esophageal squamous cell carcinoma; GO, Gene Ontology; KnowEnG, Knowledge Engine for Genomics; LUSC, lung squamous
cell carcinoma; TCGA, the Cancer Genome Atlas.
https://doi.org/10.1371/journal.pbio.3000583.g002
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studies, rather than as user manuals, which are also available through the KnowEnG website in
help text and videos (Table A in S1 Data). These case studies illustrate how the pipelines can
lead to broad insights from omics data sets and also more specific hypotheses such as genes
and pathways involved in a process can emerge from follow-up analyses, also within
KnowEnG.
Case Study 1: Clustering of pan-cancer data
As a first demonstration of the analytic capabilities of KnowEnG, we describe how the Sample
Clustering pipeline can be used to group genomic profiles in a knowledge-guided manner.
Clustering is one of the most widely used tools in bioinformatics [34] and can help identify
subgroups of samples that represent distinct biological or pathological states [35]; patient strat-
ification in cancer, where subtypes are defined based on molecular markers [36], is a prime
example. The same clustering tools are often applied to different types of genomic profiles,
including gene expression, mutation counts, copy number mutations, etc. [32]. However, clus-
tering of somatic mutation profiles of cancer patients presents a significant obstacle, because
each profile is sparse (a minuscule fraction of genomic loci are mutated) and has little direct
similarity to other profiles. As an example of a data set that presents this challenge, we worked
with somatic mutation profiles of 3,276 tumor samples spanning 12 cancer types (Appendix B
in S2 File) from the “pancan12” data set generated by the TCGA consortium [32]. (This large
data set provides a natural “ground truth,” viz., tumor type, for assessing clustering methods).
We first used the “standard” mode of KnowEnG’s Sample Clustering pipeline, viz., Hierarchi-
cal Clustering, in 6 different algorithmic configurations to identify 14 clusters (so as to match
that in the original publication [32]) of tumor samples based on their somatic mutations. (The
standard mode of this pipeline also offers K-means clustering). This failed to produce mean-
ingful clusters, and almost every clustering result exhibited strong “resolution bias” [37], with
one cluster comprising over 90% of the samples (Appendix C S2 File and Table E in S2 Data).
The sole exception was clustering with Jaccard similarity and complete linkage [38], and even
here the largest cluster had over 70% of the samples; we will refer to this below as the standard
clustering. This initial analysis illustrates the challenge in clustering somatic mutation profiles:
because of their high dimensionality and sparsity, biologically related profiles often do not har-
bor shared mutations and are not grouped together [11], ultimately leading to many small and
one or few large clusters.
Knowledge-guided clustering of mutation profiles. Knowledge-guided clustering pow-
ered by the Knowledge Network offers a possible solution to the problem just noted. Here,
prior knowledge of gene-gene relationships encoded in the network is used to recognize when
somatic mutations in different genes may be functionally related, thus allowing more subtle
forms of similarity between mutation profiles to be exploited in grouping patients. The knowl-
edge-guided option of the Sample Clustering pipeline (Fig 3A) implements the “Network-
based Stratification” (NBS) algorithm of Hofree and colleagues [11], in which a random-walk
method makes patient mutation profiles less sparse by borrowing information from the
Knowledge Network before the actual clustering step. We used knowledge-guided clustering
with the HumanNet Integrated network (hnInt) [39] as prior knowledge to group patients into
14 clusters. This yielded more size-balanced clusters; the largest cluster included 30% of the
3,276 patients. To test whether patient groups identified from mutation profiles are tied to
their phenotypic characteristics, we performed Kaplan-Meier survival analysis (Fig 3B). A log-
rank test revealed highly significant distinction across the clusters in terms of survival proba-
bilities (p = 3.7 × 10−33), which was clearly better than that observed in the standard clustering
(p = 7.4 × 10−10; Figure F in S2 File). Notably, the original clustering analysis of mutation
Knowledge-guided analysis of ‘omics’ data using the KnowEnG cloud platform
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Fig 3. Knowledge-guided sample clustering. (A) Knowledge-guided sample clustering, illustrated in the context of somatic mutation profiles of cancer
patients. Because mutations are rare, 2 patients may not have mutations to the same gene(s), and their mutual similarity will be modest. In the
knowledge-guided mode (bottom), similarities between patient profiles are detected if not only the same genes are mutated but also if genes located
proximally on a network are mutated; this “relaxed” notion of mutation profile similarity leads to improved clustering. (B) Kaplan-Meier survival
analysis of clusters from HumanNet-guided clustering of somatic mutation profiles. Each of 14 reported clusters is plotted as a separate survival curve,
and the p-value of the multivariate log-rank test is displayed. (C) Concordance between different clustering approaches, using ARI. Three of these
approaches use the Sample Clustering (sc) pipeline, with HumanNet (hnNet), STRING text mining (sText) or no network (noNet) for guidance. Two
Knowledge-guided analysis of ‘omics’ data using the KnowEnG cloud platform
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profiles by Hoadley and colleagues [32] was also knowledge-guided, relying on mutations in
similar pathways to group related samples, and survival analysis of their original sample clus-
ters produced similarly significant survival distinction (p = 4.3 × 10−29; Figure H in S2 File).
The KnowEnG Sample Clustering pipeline, although producing comparable results in terms
of survival distinction among clusters, stands out for its ease-of-use compared with executing
the multistep methods of the original analysis. For instance, the user avoids download and
harmonization of prior knowledge, installation, and configuration of multiple software, data
transformations between steps, and possibly arranging for computing resources capable of
compute-intensive steps such as bootstrap sampling (explained below).
Delving deeper into the patient clusters obtained above, we asked whether the clusters reca-
pitulate the tumor types of patients or whether they reveal new structures in the data. To this
end, we calculated the adjusted rand index (ARI) [40] between the clusters and tumor types
and repeated the process for other approaches to sample clustering, including the multiomics
Cluster-Of-Cluster-Assignment (COCA) clustering reported in the work by Hoadley and col-
leagues [32] (Fig 3C). Interestingly, although there is a high concordance between tumor type
and the COCA cluster labels of the work by Hoadley and colleagues [32] (ARI = 0.82), the
same is not true for NBS-based clusters from the KnowEnG pipeline (ARI = 0.13) or for the
pathway-based clustering of mutation profiles in the original study (ARI = 0.13). In other
words, knowledge-guided clustering finds groups of patient mutation profiles that have strong
correspondence with survival characteristics yet do not simply track tumor types, suggesting
alternative levels of molecular similarity. We explored this possibility in detail (Appendix D in
S2 File) and found the clusters to be characterized by mutations in genes from specific and dis-
tinct pathways, even when they are mixed in terms of tumor type representation.
Clustering of multiomics data. The standard clustering pipeline in KnowEnG may be
applied to any type of spreadsheet data to cluster a collection of samples, whereas the knowl-
edge-guided clustering pipeline may be used on any gene-level spreadsheet, in which rows rep-
resent genes. We showcase this capability by performing “multiomics clustering” of the same
cohort of patients as above. A major advantage of multiomics profiling of patients is that their
mutual relationships and hidden group structures revealed by each data type can be consoli-
dated into a more integrative, higher-level clustering that is more informative than any one
type of profile alone. This was demonstrated by Hoadley and colleagues [32] through their
COCA method. Mimicking their approach, we first clustered the above pan-cancer cohort
of patients based on their gene expression, methylation, copy number variation, or protein
abundance profiles (Appendix C in S2 File and Table E in S2 Data) separately, using standard
clustering. (Knowledge-guided clustering may also be used for all of these profiles except
methylation, which is not a gene-level data set). In addition, we considered our knowledge-
guided clustering of mutation data reported above and the microRNA clustering from the
original publication [32], thus arriving at 6 different ways to partition the cohort into clusters.
clustering approaches are reproductions from the Hoadley and colleagues (“tcga_mut” obtained from mutation data and “tcga_coca” obtained from
multiomics data using COCA). The sixth clustering (disease) is simply a grouping of patients by tumor type. (D) Kaplan-Meier survival analysis of 13
COCA clusters in pan-cancer multiomics data. Users may click the clock icon next to cluster assignments in the Spreadsheet Visualizer to access this
display, which uses the current grouping criterion (configurable) for survival analysis. (E) Sample Clustering of pan-cancer multiomics profiles,
displayed by the Spreadsheet Visualizer module. Patient profiles are grouped by overall cluster assignment using COCA. The top heat map (blue) shows
cluster assignments based on individual omics data types (expr, expression; RPPA, proteomic; CNV, copy number variation; methyl, methylation;
miRNA, microRNA). The heat maps below show CNV data for select genes (middle) and mutation data for select genes (bottom) for the same patients.
Users can configure the number of rows to display for each data source, the statistical criteria for selecting rows, and their sorting order. The grouping
criteria for samples (COCA cluster assignments here) can also be configured. User-selected clinical annotations of patients (primary disease in this
view; color bar second from top) may also be displayed. ARI, adjusted rand index; CNV, copy number variation; COCA,cluster of cluster assignment;
NBS, network-based stratification; STRING, search tool for recurring instances of neighboring genes.
https://doi.org/10.1371/journal.pbio.3000583.g003
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Each such clustering assigns a cluster identifier to a patient, and we can thus describe the mul-
tiomics profiles of the patient as a succinct “meta-profile” of 6 cluster identifiers. We then used
the standard clustering pipeline on these meta-profiles, arriving at 13 clusters (again mimick-
ing the original published analysis [32]) that capture the 6 different omics data sets on the
same patients. For this step, we employed the “bootstrap clustering” option of the sample clus-
tering pipeline, which typically yields more robust clustering [41]; the ease of employing this
powerful feature is another example of value added by a cloud-based infrastructure. The steps
in which different clustering results were combined into common profiles require manipula-
tions with multiple spreadsheets, each being the result of a separate cluster. KnowEnG facili-
tates these steps, as well as several other common matrix operations, through its “mini
pipelines” that are available as notebooks in a Jupyter environment (Appendix E in S2 File).
Interactive visualization. Results of the above multiomics cluster analysis were visualized
via the Spreadsheet Visualizer module of KnowEnG (Fig 3E), which in addition to displaying
multiple spreadsheets as a heat map, allows users to simultaneously visualize various other
properties of samples (e.g., cluster assignments provided by COCA, selected clinical annota-
tions such as age, survival months, and primary disease type), offers different ways of sorting,
filtering, and grouping the data and provides useful descriptive statistics, such as histograms,
in an interactive manner. The interactive visualization also allows us to easily perform survival
analysis of the displayed clusters, and we used this feature to find that the new multiomics clus-
ters are strongly concordant with tumor type (ARI = 0.72) and exhibit differences in survival
probabilities (p = 1.0 × 10−150; Fig 3D, Appendix F in S2 File) far more prominently than the
mutation-only analyses had revealed. The Spreadsheet Visualizer is a powerful data explora-
tion and preliminary analysis tool in its own right (see Appendix G in S1 File for details) and
can be utilized independently of the clustering pipeline.
Clustering for patient stratification. As an illustration of how the Sample Clustering
pipeline may be used for patient subtyping [36], we next clustered breast cancer patients in the
METABRIC data set [42] based on genes related to the epithelial to mesenchymal transition
(EMT), which is a process involved in metastasis. Following the approach in the work by
Emad and colleagues [43], we clustered patients into 2 groups based on the expression of their
EMT-related genes (Appendix G in S2 File). Although standard mode of Sample Clustering
did not result in clusters with distinct survival probabilities, the knowledge-guided mode
achieved significant Kaplan-Meier log-rank p-values using either the STRING [44] text-
mining interaction network (“sText;” p = 3.1 × 10−4) or the HumanNet “hnInt” network
(p = 7.6 × 10−4; Figures L and M in S2 File).
Case Study 2: Gene prioritization for tumor types
A routinely conducted analysis of high-throughput omics profiles is in the determination of
genes associated with particular phenotypic conditions or biological processes of interest. Dis-
covery of differentially expressed genes [45] by contrasting transcriptomic profiles before and
after treatment or in case versus control experiments, or of genes whose expression correlates
with a numeric phenotype such as drug response [46] are prime examples. The Gene Prioriti-
zation pipeline in KnowEnG offers this functionality, given a spreadsheet of omics data (genes
x samples) and a “phenotype spreadsheet” (phenotypes x samples) that represents one or more
phenotypic labels for each sample in the omics spreadsheet. As a simple demonstration of this
pipeline, we analyzed expression data from tumor samples in the pancan12 data set introduced
above, comparing each tumor type with all others using a t test to identify significant differ-
ences in individual gene expression between the groups; this is the standard version of the
pipeline (Fig 4A, Appendix A in S3 File).
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Fig 4. Knowledge-guided gene prioritization. (A) In standard mode (top), each gene’s expression is tested for association with phenotypic labels, e.g.,
with a t test. In the (bottom) knowledge-guided mode (ProGENI algorithm), each gene’s expression is first transformed by taking into account
expression levels of its network neighbors, and these “network-smoothed” expression values are tested for association with phenotype. The resulting
ranking of genes is subjected to second phase of network-based smoothing to obtain the final ranking. (B) Visualization of results from the Gene
Prioritization pipeline, used here to identify top genes associated with each tumor type (based on expression data). Users may choose to analyze and
visualize results for multiple phenotypes together and configure how many top genes per phenotype the report should include. (C) Known driver genes
for each tumor type that are highly prioritized by standard and/or knowledge-guided modes of Gene Prioritization. (D) Comparison between tumor
type–related genes identified using the Gene Prioritization pipeline in standard mode (“GP_noNet”) or knowledge-guided mode using HumanNet
(“GP_hnInt”), based on their enrichment for GO terms. The axes represent the negative logarithm (base 10) of p-value of enrichment between the set of
highly prioritized genes (from either method) for a tumor type and the most enriched GO category for that set. GO, gene ontology.
https://doi.org/10.1371/journal.pbio.3000583.g004
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Knowledge-guided gene prioritization. KnowEnG also offers a knowledge-guided mode
of this pipeline, where the ProGENI algorithm of Emad and colleagues [47] is used to incorpo-
rate a network encoding prior knowledge into the identification of phenotype-related genes
(Fig 4A), using random walk-based techniques similar to those used in the NBS clustering
approach [11]. We had previously tested ProGENI on the task of prioritizing drug response–
related genes. Through systematic benchmarking, experimental validations and literature sur-
veys we showed that it identifies phenotype-related genes more accurately compared with sim-
ple statistical methods as well as machine learning methods that do not utilize prior knowledge
[48]. We now applied this algorithm, via the knowledge-guided gene prioritization pipeline, to
identify top genes associated with each tumor type, based on expression data (Fig 4B, Appen-
dix A in S3 File). (KnowEnG allows this analysis to be performed for all tumor types through
one simple operation, rather than repeat it for each tumor type separately).
Gene prioritization finds driver genes. For an independent assessment of the above
results, we compared the top 100 genes for each tumor type with drivers of that cancer as
cataloged in the IntOGen database [49] based on mutation and gene fusion data (Fig 4C).
We observed overlaps between the 2 lists; for example, in head and neck squamous cell carci-
noma (HNSCC), 6 of the highly prioritized genes are known drivers (Fisher’s exact test
p = 8.2 × 10−4; Figure A in S3 File). A similar assessment of genes reported by the standard
pipeline (without knowledge-guidance) revealed fewer overlaps with respective driver sets for
all but 2 tumor types (Fig 4C). Often, common driver genes were identified by both versions of
the pipeline, e.g., GATA3 for breast cancer (BRCA), but in many cases the knowledge-guided
version reported known drivers that were missed by the standard pipeline, e.g., FOXA1 for
BRCA, NRAS and KRAS for acute myeloid leukemia (AML), and CDH1, CTNNB1, and
EGFR for HNSCC. (ESR1, a well known marker of BRCA [50], was ranked in the top 1.2% of
all genes for BRCA, but ranked much worse for other tumor types). Similar conclusions were
reached when we repeated the assessment using a larger external set of tumor type drivers,
based on both IntOGen and COSMIC databases [49, 51] (Appendix A in S3 File).
Functional enrichment of prioritized genes. To gain further insights into the highly
ranked genes reported for each tumor type in the above analysis, we subjected them to func-
tional enrichment analysis through the Gene Set Characterization pipeline, whose standard
version uses the Fisher’s exact test to assess the enrichment of a gene set for prespecified anno-
tations. This revealed various interesting pathways and GO terms as being significantly associ-
ated with each tumor type (Appendix B in S3 File). For instance, glioblastoma (GBM)-related
genes found by ProGENI were significantly associated with receptor proteins in the presynap-
tic active zone and excitatory synapse, whose altered expression can enhance gliomas ability to
grow and survive [52] (Bonferroni corrected p = 6.0 × 10−3). Similarly, AML-related genes
were enriched for platelet activation, shown to be related to blast proliferation [53] (Bonferroni
corrected p = 2.0 × 10−6). The extent to which significant functional properties can be associ-
ated with a gene set extracted by genomics analyses is one measure of the utility of that gene
set [54]. Thus, we summarized the results of gene set characterization by noting the most sta-
tistically significant functional enrichment (of genes prioritized) for each tumor type. We
noted that when the same process was repeated using genes reported by the standard gene
prioritization pipeline the functional enrichments tended to be less prominent (Fig 4D), thus
providing further evidence of the value of knowledge-guided gene prioritization. The same
conclusion was reached when a different network (STRING text mining) was used in gene pri-
oritization instead of the HumanNet integrated network (Appendix B in S3 File).
Pan-cancer signature from prioritized genes. Sets of genes of particular relevance to a
tumor type are often used as a “signature” of that tumor, i.e., a representative gene set that cap-
tures much of the diagnostic or prognostic value of the entire expression profile. The PAM50
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signature of breast cancer is a prime example [36], being used for patient stratification based
on expression of a small set of genes. We asked if the tumor-associated genes prioritized above
for each tumor type together form a similar signature with prognostic value in a pan-cancer
context. Indeed, we observed that pan-cancer subtypes obtained from clustering only the
expression of the tumor-associated genes were just as predictive of survival (Kaplan-Meier
p = 3.8 × 10−175) as the above-mentioned clusters based on entire expression profiles
(p = 1.2 × 10−169; see Appendix C in S3 File). This finding was robust to the use of different
networks (or no network) in the gene prioritization step.
Case Study 3: Signature analysis and gene set characterization on a third-
party system
Our next case study makes use of a fourth pipeline—Signature Analysis (Fig 5A)—to study a
transcriptomic data set of ESCC samples [33] and also showcases how KnowEnG tools can be
invoked on computing infrastructures external to the platform (Fig 5B). Although the Kno-
wEnG web portal offers a flexible graphical user interface, advanced users performing bioin-
formatics analysis on a different computing framework may prefer to avail of KnowEnG
pipelines on that external framework directly, without tedious transfer of data, intermediate
results, or code from one system to another.
Interoperability. KnowEnG currently offers such seamless interoperability with the
SB-CGC, which provides researchers with secure access to public data sets such as TCGA and
TARGET. We used SB-CGC to access RNA-seq data for the previously reported ESCC tumor
samples [33] and created a transcriptomic spreadsheet (genes x samples) for further analysis
with KnowEnG pipelines in the SB-CGC environment (Fig 5B, Appendix A in S4 File). This is
made possible by the publication of KnowEnG pipelines as native workflows on the SB-CGC,
with simple graphical interfaces, and creates opportunities for synergistic use of functionalities
offered by these 2 powerful genomics computing platforms. (External availability of KnowEnG
pipelines includes seamless access to the massive Knowledge Network that supports knowl-
edge-guided analysis). Interoperability is an important tenet of the emerging vision of comput-
ing infrastructures of the future. It was achieved by using 2 emerging technologies—Docker
containers [5] to make the underlying software of each pipeline portable and Common Work-
flow Language (CWL) [55] to provide a standardized description of the pipeline (Appendix H
in S1 File). This alternative mode of KnowEnG usage also facilitates reproducibility and reus-
ability; e.g., users may share their project on SB-CGC with collaborators. Thus, by ensuring
interoperability and reusability, in addition to accessibility and findability already offered by
the cloud-based web platform, the KnowEnG-CGC joint framework takes a major step toward
the realization of the FAIR principles of modern data science.
Signature analysis for patient subtyping. Operating within the SB-CGC framework, we
performed a signature analysis of 79 ESCC patients as reported in the original TCGA publica-
tion. Signature analysis [56] is a widely used method in cancer informatics and has been used
for various tasks such as identifying subtypes [36], characterizing purity of tumor samples
[57], determining the abundance of immune cells in tumor microenvironment [58], character-
izing transitions involved in the invasion-metastasis cascade [43], etc. Here, given a spread-
sheet of transcriptomic profiles of a cohort of patients, and a second spreadsheet of
predetermined expression signatures, the pipeline finds the closest matching signature for
each patient (Fig 5A). This often allows existing insights about the signature to shed light on
clinical characteristics of the patient based on their molecular profile. Following the original
publication, we matched ESCC samples to signatures representing 4 subtypes of LUSC [59],
because the 2 cancers are anatomically adjacent and previously established subtypes of LUSC
Knowledge-guided analysis of ‘omics’ data using the KnowEnG cloud platform
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000583 January 23, 2020 12 / 25
may be relevant to ESCC as well (Appendix B in S4 File). We noted that one cluster of ESCC
patients (“ESCC1,” identified in the original publication) mostly (65%) resembled the classical
subtype of LUSC, whereas the second main cluster (“ESCC2”) mostly (63%) matched the basal
subtype of LUSC (Fig 5C), and fewer samples matched the primitive and secretory subtypes.
The correspondence discovered between ab initio detected ESCC subtypes and previously
reported LUSC subtypes is generally consistent with the observations of the original TCGA
esophageal carcinoma analysis, who note that tumors matching the classical expression sub-
type also had similar somatic alterations to the subtype and were associated with poor progno-
sis and chemotherapeutic resistance. To highlight the convenience of co-localizing the analysis
workflows with the data on the SB-CGC, we reran the analysis by simply substituting an alter-
nate TCGA data set of LUSC tumor samples, again finding the classical subtype (40%) to be
the most prevalent (Fig 5D).
Pathway analysis of subtype-associated genes. Having categorized ESCC patients into
one of 4 subtypes using signature analysis, we next used the standard gene prioritization pipe-
line to identify genes associated with each subtype and subjected the resulting subtype-associ-
ated gene lists (Appendix C in S4 File) to further analysis using the gene set characterization
pipeline introduced above. We now used the knowledge-guided version of this pipeline, which
instead of performing the traditional “enrichment test” between sets [60], uses a random-walk
algorithm with the user-provided gene set as “restart nodes,” to find property nodes of the
Knowledge Network that are most related to the given gene set (Fig 6A). This class of algo-
rithms has been successfully used to quantify the relationship between network nodes in a vari-
ety of domains such as web mining [61] and social network analysis [62]. The KnowEnG
Fig 5. Signature analysis pipeline. (A) Each user-uploaded expression profile (sample) is matched against expression profiles in a predetermined
collection (signatures) and match scores for all sample-signature pairs are reported by the pipeline. (B) Signature Analysis and other KnowEnG
pipelines can be executed seamlessly on the third-party platform of SB-CGC that hosts a large repository of cancer data and associated tools. The
pipelines are published on SB-CGC as a native workflow and the Knowledge Network is transferred “under the hood” from the KnowEnG Cloud when
needed by a pipeline. (C) Signature Analysis of 79 ESCC samples, distributed into 3 subgroups, matched against 4 LUSC signatures (subtypes) using
Spearman’s Correlation Coefficient. (D) Signature analysis of 551 LUSC samples available on the SB-CGC, matched against 4 LUSC signatures. ESCC,
esophageal squamous cell carcinoma; KnowEnG, Knowledge Engine for Genomics; LUSC, lung squamous cell carcinoma; SB-CGC, Seven Bridges
Cancer Genomics Cloud.
https://doi.org/10.1371/journal.pbio.3000583.g005
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pipeline uses an implementation called “DRaWR” [24], the main advantage of which com-
pared to enrichment tests is that it examines not only properties with which the given genes
are annotated but also the properties with which genes related to the given genes are annotated
(Appendix C in S4 File). We have previously used DRaWR to characterize gene sets in Dro-
sophila development [24] and cancer [63]. Here, we used the DRaWR-based knowledge-
guided gene set characterization pipeline with the HumanNet Integrated network [39] as the
underlying network to identify, for ESCC subtype-related genes, the most related pathways in
the Enrichr Pathways Collection [64]. (The pipeline offers several options for the network as
well as the properties to be ranked; see Appendix C in S4 File). As a point of contrast, we also
analyzed the gene sets with the standard version of the pipeline that uses the traditional Hyper-
geometric test approach [65]. Fig 6B tabulates 12 discovered pathway associations for ESCC
subtypes that were reported by the DRaWR-based version of the pipeline but not by the stan-
dard version. Even though these associations do not meet the traditional criterion of signifi-
cant set overlap, there is support in the literature for 7 of the 12 associations. Moreover, the
top-ranked association was between basal subtype of ESCC and the gastric cancer network,
which is credible given the close relationship between ESCC and gastric cancer, which are
anatomically adjacent and share several risk factors [66]. Surprisingly, this association was not
detected by the enrichment test performed in the standard pipeline. Another interesting exam-
ple is the primitive subtype being linked to FOXM1 transcription factor network but only by
the DRaWR-based pipeline. FOXM1 has been found to be related to ESCC progression [67]
and to be a potential drug target; our finding of a specific association with the primitive sub-
type of ESCC suggests that the tumor subtype may be an important factor to consider in its
Fig 6. Knowledge-Guided GSC. (A) Common approaches to GSC examine the overlap (top) between a user-provided gene set (e.g., genes A, D, E) and
genes in a pathway (e.g., A, D, B in pathway P1). In the (bottom) knowledge network-guided mode (algorithm DRaWR), the association between 2 gene
sets is based not only on direct overlap between them but also on network-based proximity between them. (B) LUSC subtype-associated pathways
found exclusively with network-guided GSC pipeline using DRaWR. (C) Pathways associated with LUSC subtypes found by standard as well as
network-guided GSC pipelines. GSC, gene set characterization; LUSC, lung squamous cell carcinoma.
https://doi.org/10.1371/journal.pbio.3000583.g006
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therapeutic significance. We also found several subtype-pathway associations reported by both
versions of the pipeline (Fig 6C). For instance, both the basal and classical subtypes were asso-
ciated with NRF2 pathway [68], the secretory subtype was linked to Syndecan-1 mediated sig-
naling event [69], and the primitive subtype to oxidation by Cytochromes P450 [70]. A total of
6 of the 13 such associations found by enrichment-based as well as DRaWR-based gene set
characterization had circumstantial evidence in the literature.
In summary, this case study illustrates how different KnowEnG pipelines, in this case,
beginning with signature analysis and followed by gene prioritization and gene set characteri-
zation, can be used in a workflow to not only relate patient profiles to previously reported can-
cer subtypes but also to glean novel insights about genes and pathways differentiating patients
matched to different subtypes. We performed these analyses on a system external to KnowEnG
(i.e., SB-CGC), but the same workflow may be executed on the KnowEnG platform as well,
and the interface facilitates easy “stringing” of multiple pipelines to enable such workflows.
Discussion
KnowEnG is an analysis engine designed and implemented with the needs and trends of mod-
ern genomics research in mind. KnowEnG offers a vision of genomic computing that is com-
plementary to the dominant paradigm where software packages (e.g., in R or python) are
installed on the user’s computer and executed locally. The current paradigm is convenient as
long as data sets predominantly reside locally, but with the on-going movement toward mas-
sive data sets in the public domain [71] and a clear need for moving tools to co-locate with
these data, we expect the alternative paradigm embraced by KnowEnG to be increasingly rele-
vant. Its main platform provides a convenient way to analyze the user’s uploaded spreadsheets
while exploiting massive knowledgebases encoded in the Knowledge Network, and its interop-
erability with major cloud-based platforms such as SB-CGC showcases the advantages of tools
moving to data sources while maintaining the convenient “illusion” of local computation.
Comparison with existing frameworks
KnowEnG embodies many of the powerful ideas to have emerged in the genomics research
over the last decade, including knowledge-guided analysis, cloud-based storage and comput-
ing, machine learning and network-mining algorithms, and the FAIR principles for broader
impact. KnowEnG draws inspiration from existing analytic tools and systems that have
brought the above ideas to the fore. For instance, if we consider noncommercial platforms
with web portals that offer multiple analytics functionalities for genomics data sets, some
prominent examples that come to mind include Galaxy [72], FireCloud/Terra [73], cBioPortal
[74], NCI Genomic Data Commons (GDC) Data Portal [2], GenePattern [75], GeneWeaver
[76], GeneMANIA [77], and GenomeSpace [78], among others. Below we clarify the unique
position of KnowEnG in the rich milieu of genomics platforms available today.
The Galaxy platform provides convenient wrappers around popular external tools, mainly
for next generation sequencing data analysis and many other tasks such as meta-genomics,
phylogenetics, and sequence analysis that are outside the scope of KnowEnG. However, Galaxy
is not geared toward knowledge-guided analysis of users’ omics data spreadsheets, and its
“downstream” analysis functions do not include sample clustering, gene prioritization for
numeric phenotypic scores, or signature analysis, nor do they include the powerful spreadsheet
visualization capability of KnowEnG. FireCloud/Terra similarly allows users to perform a vari-
ety of analyses of their own data as well as hosted data sets but does not offer, as KnowEnG
does, knowledge-guided analysis or a rich visual interface. The popular cancer-related plat-
forms of cBioPortal and NCI GDC are mainly geared toward visualization and exploration of
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omics spreadsheets extracted from the data sets they host rather than users’ spreadsheets and
also differ significantly from KnowEnG in terms of analytics tasks offered, including knowl-
edge-guided tools. Moreover, FireCloud, cBioPortal, and NCI GDC are entirely focused on
cancer data analysis. In contrast, KnowEnG tools are meant for analysis of user-provided
omics spreadsheets from any biological domain in any of its 20 currently supported species.
GenePattern is a web-based portal that offers a number of modules for genomics data anal-
ysis, similar to KnowEnG pipelines, with similar functions. However, these general-purpose
machine learning tools do not fall in the genre of knowledge-guided analysis and do not offer
the option of exploiting prior knowledge. On the other hand, GeneWeaver and GeneMANIA
are online portals for knowledge-guided analysis of user data but are limited to gene sets, simi-
lar to KnowEnG’s GSC pipeline, and do not provide tools such as sample clustering and gene
prioritization for spreadsheet analysis. Another popular modern platform, GenomeSpace, is a
warehouse of diverse virtual workflows that connect several external tools and databases and
that have some overlaps with KnowEnG functionalities. However, it does not perform any
analysis itself and acts more as a data highway for passing data from one tool to another and is
thus dependent on external tools and computing platforms to ensure scalability of its
workflows.
We reserve a special mention of the ‘geWorkBench’ [79], an open-source platform provides
standard tools for common tasks such as sample clustering, gene prioritization, and gene set
enrichment, comparable to “baseline” options in the corresponding KnowEnG pipelines, as
well as specialized tools [80–83] for analyzing a gene expression spreadsheet and a co-expres-
sion network simultaneously. However, geWorkBench has to be installed on the user’s
machine, and its web version has a small subset of tools from its desktop version, reflecting the
challenges of offering a centralized web portal to compute-intensive tools with complex inputs.
KnowEnG pipelines, on the other hand, embrace the use of computationally intensive but
often trivially parallelizable techniques such as bootstrap sampling because of the scalability
afforded by cloud computing.
In summary, a careful comparison of the features and goals of some of the major contempo-
rary analytical frameworks reveals that KnowEnG brings complementary capabilities to the
user, either in terms of the actual analyses offered, in allowing knowledge-guided analysis, in
focusing on user-provided spreadsheet data analysis, in providing a consolidated cloud-based
back-end for scalable computation, or in its online interface for visualizing data and results.
Importantly, KnowEnG also supports analysis for 20 species currently, making its scope
broader than several of the above-mentioned tools that are restricted to human genomic analy-
sis. This is a major feature because knowledge-guided analysis requires integration of prior
knowledgebases with tools in a species-specific manner.
Applications to other biological domains
KnowEnG pipelines analyze spreadsheets of genes (rows) by samples (columns), which tabu-
late numeric information about each gene in each sample. The information may come from a
variety of sources, e.g., high-throughput transcriptomics assays using various technologies,
mutation counts at the gene level, copy number variations, etc. The analytical approaches do
not make strong assumptions about the source of the data and are, as a result, applicable to
any number of biological domains, not just cancer, as we discuss next.
The gene prioritization pipeline may be used in any scenario where a spreadsheet of gene-
level measurements (expression levels, mutation counts, copy numbers, epigenomic measure-
ments, etc). is available on a collection of samples, along with a phenotypic score for each sam-
ple. For instance, Emad and colleagues [47] used this pipeline to identify genes whose basal
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expression in a cancer cell line is predictive of the cell line’s response to a cytotoxic treatment.
Similar analyses have been performed in other published studies [48], although without incor-
porating a knowledge network. Other examples of potential applications to gene prioritization
for numeric phenotypes include identifying genes whose brain expression levels are predictive
of pheromone response in honeybees [84], discovering genes predictive of growth rate in bac-
teria or yeast [85], and identifying gene families whose size (number of paralogs) in a species is
correlated with a numeric score of that species, e.g., eusociality index in bees [86]. Indeed, the
potential of this line of analysis is evidenced by the recent publication of a tool specifically for
relating expression to traits (“TraitCorr” [87]) as an R package. The task of identifying differ-
entially expressed genes between 2 conditions (binary phenotypes) can also be performed, in a
knowledge-guided manner, using the gene prioritization pipeline. The high utility of this task
needs no introduction, and many tools are available for it [88]. The unique value of the Kno-
wEnG pipeline is that common statistical tests used for this task, e.g., t test or EdgeR [89], can
be combined with “smoothing” of gene expression values based on the Knowledge Network as
well as subjected to “bootstrapping” for robustness. (We and others have already demonstrated
the value of network-smoothing and bootstrapping in prior work on gene prioritization [47]).
These additional features of the pipeline are well supported by a cloud-based platform that
offers easy scalability and prestored knowledge networks, thus avoiding the hassles of main-
taining compute clusters and downloading large networks for a more traditional “local compu-
tation” such as those using Bioconductor packages [90].
Clustering is a pervasive operation in bioinformatics and finds uses in a large number of
scenarios. Clustering may be performed within KnowEnG for any of the 20 species supported
by it, for any set of experimental conditions, and for any type of omics data that assign numeric
measurements to genes, to reveal hidden groupings among the conditions. Whereas the com-
mon tools for gene expression clustering focus on the task of grouping genes, the KnowEnG
Sample Clustering pipeline is geared toward finding groups of samples/conditions that have
similar expression profiles. This distinction is crucial to its use of a knowledge network to
guide the clustering, lends it a complementary strength, and is expected to be of increasing
utility in the future as the practice of profiling tissue samples from individuals grows more
popular [91]. The most common uses of sample clustering are in identifying subgroups in can-
cer patients, based on transcriptomic as well as other omics data sets, e.g., identifying breast
cancer subgroups from copy number variations [92], colon cancer subgroups from gene
expression data [93], refinement of breast cancer subtypes based on microRNA expression
profiles [94], subtyping of different cancers from somatic mutation data [95], to name a few.
Other uses of clustering to group samples include clustering of type 2 diabetes patients as well
as obese and healthy subjects to find that type 2 diabetes and obesity have similar expression
profiles [96], grouping of brain transcriptomes of honeybee nurses and foragers of different
ages to show that each behavioral group has similar profiles [97], clustering of Arabidopsis
plants treated with plant activators [98], etc.
The GSC pipeline addresses one of the most commonly performed tasks in genomics analy-
sis, which is sometimes referred to as gene set enrichment analysis (GSEA) and often per-
formed using the GSEA tool [99] or through hypergeometric tests. Studies that use this
analytical operation are too numerous to list here, but its popularity is evidenced by the huge
following that online tools such as DAVID [60] and Enrichr [64] have. We nevertheless
included this pipeline in KnowEnG because it is a natural follow-up for the gene prioritization
pipeline, and we expect users to make use of it every time they identify top genes associated
with a phenotype. Moreover, the KnowEnG pipeline offers 2 complementary approaches to
the above task—the popular approach based on hypergeometric tests (as in DAVID) and a
novel approach based on random walks with restart (RWR), which we have published
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previously [24] and whose unique value we further demonstrate in Appendix D in S4 File. The
RWR-based method not only provides an alternative approach to identifying pathways, GO
terms, etc., most relevant to a given set of genes, it does so while accounting for gene-gene rela-
tionships encoded in a knowledge network, according unique value to the KnowEnG pipeline.
We have also published the use of the RWR-based method to characterize gene sets arising out
of a brain transcriptomic study of social behavior in 3 different species [100].
Flexibility of KnowEnG functionalities
While KnowEnG offers analysis functionalities that have broad applicability, we recognize that
there will be many scenarios in which the scientist may require modifications to those func-
tionalities or add components to the available pipelines for maximum benefit. There are a few
straightforward steps required for a developer to adding a new tool to the KnowEnG system
(detailed in Appendix I in S1 File). All KnowEnG pipelines are published as Docker containers
and also have CWL descriptions of their inputs, outputs, and execution steps. Such “packag-
ing” of pipelines not only allows them to be used on any platform as part of the user’s estab-
lished workflows, it also allows the user to add their own custom tools, implemented in R or
other languages, into the KnowEnG framework. In some cases, the user may wish to execute a
particular KnowEnG pipeline repeatedly, with varying configurations. They may achieve this
relatively easily through the containerized versions of KnowEnG tools. Another desired
dimension of flexibility in KnowEnG analytics is that of the Knowledge Network. Although we
provide several predetermined networks as available options to choose from when running a
KnowEnG pipeline, the user may wish to utilize a custom network specialized for their domain
of enquiry. This is allowed within the KnowEnG framework, via the Network Prepper tool
(Appendix E in S1 File). Flexibility is also supported by the multiple modes of access for Kno-
wEnG tools, including the SB-CGC platform and Jupyter notebooks, which provide program-
ming-savvy users several options for integration with other tools.
Despite our efforts to add provisions for flexible uses of KnowEnG functionalities, we rec-
ognize that the system will not be a one size fits all solution for bioinformatics analysis. We
expect that most genomics projects will have an “upstream” analysis component in which
the data are processed in a more domain- and technology-dependent manner, outside of
KnowEnG. Our hope is that such upstream analysis will often result in creation of omics
spreadsheets similar to the ones used in our case studies and that their downstream analysis
(such as sample clustering, gene prioritization, GSC) can be carried out in the KnowEnG
framework in a more universal manner, without the need for unduly cumbersome
customizations.
Material and methods
The details of the data sets and KnowEnG analysis pipelines used in this article are fully
described in the supporting information. For each of the 3 case studies, there is a correspond-
ing supporting information file (S2 File, S3 File, and S4 File) that details the methods related to
that case study in several appendices. These appendices also include additional interpretations
for each analyses as well as all of the nondefault run parameters needed to reproduce the
results. Many sections contain links to additional resources in which the actual code, contain-
ers, or compute servers can be found. Specific instructions for easily reproducing the main
analyses on the KnowEnG platform from the 3 case studies are available in Appendix F in S1
File. S1 File also contains additional information about the design and capabilities of the com-
ponents of the KnowEnG platform.
Knowledge-guided analysis of ‘omics’ data using the KnowEnG cloud platform
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000583 January 23, 2020 18 / 25
Supporting information
S1 File. Notes on the KnowEnG system. Nine appendices of supplemental commentary and
additional resources describing the KnowEnG system. KnowEnG, Knowledge Engine for
Genomics.
(PDF)
S2 File. Methods for sample clustering case study. Seven appendices describing the data,
pipelines, methods, and additional analyses that relate to the first case study of performing
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